Paul Tudor Jones Ab Cellera Biologics Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 90,734 shares of ABCL stock, worth $247,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,734

Holding current value

$247,703

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.29 - $5.97 $389,248 - $541,681	90,734 New	90,734 $411,000
Q3 2023 Nov 15, 2023	BUY	$4.6 - $7.95 $8,546 - $14,771	1,858 Added 10.18%	20,105 $92,000
Q2 2023 Aug 14, 2023	BUY	$5.66 - $7.59 $990 - $1,328	175 Added 0.97%	18,247 $117,000
Q1 2023 May 15, 2023	BUY	$7.31 - $11.18 $17,719 - $27,100	2,424 Added 15.49%	18,072 $136,000
Q4 2022 Feb 14, 2023	BUY	$9.48 - $14.52 $3,810 - $5,837	402 Added 2.64%	15,648 $159,000

Q3 2022 Nov 14, 2022	BUY	$9.2 - $13.68 $45,788 - $68,085	4,977 Added 48.47%	15,246 $151,000
Q2 2022 Aug 15, 2022	SELL	$5.72 - $10.65 $62,004 - $115,446	-10,840 Reduced 51.35%	10,269 $109,000
Q1 2022 May 16, 2022	BUY	$7.46 - $14.14 $157,473 - $298,481	21,109 New	21,109 $206,000
Q4 2021 Feb 14, 2022	SELL	$12.99 - $17.73 $196,421 - $268,095	-15,121 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$14.85 - $21.34 $959,354 - $1.38 Million	-64,603 Reduced 81.03%	15,121 $303,000
Q2 2021 Aug 16, 2021	BUY	$20.19 - $34.17 $1.61 Million - $2.72 Million	79,724 New	79,724 $1.75 Million

Others Institutions Holding ABCL

# of Institutions

171

Shares Held

120M

Call Options Held

264K

Put Options Held

254K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $778M
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account